Johnson & Johnson CFO Joseph Wolk: ‘You can’t heap enough praise on the pharma unit’
Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease treatment, Tremfya, and said it plans to spin off its hips-and-knees business next year.
